| Hydroxyurea |
biorxiv |
hydroxyurea hydroxycarbamide cytoreduction polycythemia vera essential thrombocythemia resistance intolerance |
Targets hydroxyurea-specific cytoreduction, resistance, and intolerance in PV/ET — not covered by any existing query which focus on JAK inhibitors, interferons, epigenetics, or other agents. |
manually-archived |
| Hydroxyurea |
pubmed |
"hydroxyurea"[Title/Abstract] AND ("polycythemia vera"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract] OR "myeloproliferative"[Title/Abstract]) AND (resistance[Title/Abstract] OR intolerance[Title/Abstract] OR cytoreduction[Title/Abstract] OR "hematocrit"[Title/Abstract]) |
Targets hydroxyurea specifically in MPN contexts with clinically relevant modifiers (resistance, intolerance, cytoreduction, hematocrit) that none of the existing queries cover. |
active |
| ASTX727 + Venetoclax combination (CMML / MDS-MPN) |
biorxiv |
decitabine cedazuridine venetoclax CMML myelodysplastic myeloproliferative BCL-2 |
Targets the specific oral HMA (ASTX727/decitabine-cedazuridine) plus venetoclax combination in CMML/MDS-MPN, which is not covered by existing queries that focus on azacitidine, JAK inhibitors, or other mechanisms. |
manually-archived |
| ASTX727 + Venetoclax combination (CMML / MDS-MPN) |
pubmed |
("ASTX727"[Title/Abstract] OR "decitabine cedazuridine"[Title/Abstract] OR "oral decitabine"[Title/Abstract]) AND "venetoclax"[Title/Abstract] AND ("CMML"[Title/Abstract] OR "chronic myelomonocytic leukemia"[Title/Abstract] OR "MDS/MPN"[Title/Abstract] OR "myelodysplastic myeloproliferative"[Title/Abstract]) |
Targets the specific oral HMA + BCL-2 inhibitor combination in the CMML/MDS-MPN population, which no existing query covers — existing queries touch hypomethylating agents broadly but not ASTX727 specifically nor its pairing with venetoclax. |
demoted |
| Inflammatory cytokine signaling |
biorxiv |
interleukin cytokine TNF myeloproliferative neoplasm inflammation constitutional symptoms |
Targets the specific inflammatory cytokine signaling mechanism (IL-6, IL-8, TNF-alpha, constitutional symptoms) in MPNs, which is not covered by any existing query focused on JAK/STAT, clonal hematopoiesis, specific drugs, or mutations. |
manually-archived |
| Inflammatory cytokine signaling |
pubmed |
("IL-6"[Title/Abstract] OR "interleukin-6"[Title/Abstract] OR "TNF-alpha"[Title/Abstract] OR "tumor necrosis factor"[Title/Abstract] OR "IL-8"[Title/Abstract]) AND ("myeloproliferative"[Title/Abstract] OR "myelofibrosis"[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract]) |
Targets the specific cytokines (IL-6, IL-8, TNF-alpha) named in the page's current understanding in the MPN context, which no existing query covers. |
active |
| MPL mutations |
biorxiv |
MPL W515 mutation thrombopoietin receptor JAK2 activation essential thrombocythemia myelofibrosis |
Targets MPL-specific activating mutations (W515L/K) and their mechanistic role in ET/PMF, which the existing CALR query only peripherally touches and no other query addresses directly. |
manually-archived |
| MPL mutations |
pubmed |
"MPL"[Title/Abstract] AND ("W515L"[Title/Abstract] OR "W515K"[Title/Abstract] OR "MPL mutation"[Title/Abstract] OR "thrombopoietin receptor"[Title/Abstract]) AND ("essential thrombocythemia" OR "myelofibrosis" OR "myeloproliferative") |
Targets MPL-specific activating mutations (W515L/K) and the thrombopoietin receptor directly, which no existing query covers; the closest existing query only mentions MPL as a secondary term alongside CALR. |
active |